Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Synthesis and SAR of potent EGFR/erbB2 dual inhibitors.
Zhang YM, Cockerill S, Guntrip SB, Rusnak D, Smith K, Vanderwall D, Wood E, Lackey K. Zhang YM, et al. Among authors: lackey k. Bioorg Med Chem Lett. 2004 Jan 5;14(1):111-4. doi: 10.1016/j.bmcl.2003.10.010. Bioorg Med Chem Lett. 2004. PMID: 14684309
Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis.
Bramson HN, Corona J, Davis ST, Dickerson SH, Edelstein M, Frye SV, Gampe RT Jr, Harris PA, Hassell A, Holmes WD, Hunter RN, Lackey KE, Lovejoy B, Luzzio MJ, Montana V, Rocque WJ, Rusnak D, Shewchuk L, Veal JM, Walker DH, Kuyper LF. Bramson HN, et al. Among authors: lackey ke. J Med Chem. 2001 Dec 6;44(25):4339-58. doi: 10.1021/jm010117d. J Med Chem. 2001. PMID: 11728181
Aza-stilbenes as potent and selective c-RAF inhibitors.
McDonald O, Lackey K, Davis-Ward R, Wood E, Samano V, Maloney P, Deanda F, Hunter R. McDonald O, et al. Among authors: lackey k. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5378-83. doi: 10.1016/j.bmcl.2006.07.063. Epub 2006 Aug 4. Bioorg Med Chem Lett. 2006. PMID: 16890436
The discovery of potent cRaf1 kinase inhibitors.
Lackey K, Cory M, Davis R, Frye SV, Harris PA, Hunter RN, Jung DK, McDonald OB, McNutt RW, Peel MR, Rutkowske RD, Veal JM, Wood ER. Lackey K, et al. Bioorg Med Chem Lett. 2000 Feb 7;10(3):223-6. doi: 10.1016/s0960-894x(99)00668-x. Bioorg Med Chem Lett. 2000. PMID: 10698440
The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.
Rusnak DW, Affleck K, Cockerill SG, Stubberfield C, Harris R, Page M, Smith KJ, Guntrip SB, Carter MC, Shaw RJ, Jowett A, Stables J, Topley P, Wood ER, Brignola PS, Kadwell SH, Reep BR, Mullin RJ, Alligood KJ, Keith BR, Crosby RM, Murray DM, Knight WB, Gilmer TM, Lackey K. Rusnak DW, et al. Among authors: lackey k. Cancer Res. 2001 Oct 1;61(19):7196-203. Cancer Res. 2001. PMID: 11585755
Comparison of the biochemical and kinetic properties of the type 1 receptor tyrosine kinase intracellular domains. Demonstration of differential sensitivity to kinase inhibitors.
Brignola PS, Lackey K, Kadwell SH, Hoffman C, Horne E, Carter HL, Stuart JD, Blackburn K, Moyer MB, Alligood KJ, Knight WB, Wood ER. Brignola PS, et al. Among authors: lackey k. J Biol Chem. 2002 Jan 11;277(2):1576-85. doi: 10.1074/jbc.M105907200. Epub 2001 Nov 5. J Biol Chem. 2002. PMID: 11696537 Free article.
72 results